Jeffrey S Stehouwer
Overview
Explore the profile of Jeffrey S Stehouwer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stehouwer J, Huang G, Saturnino Guarino D, Debnath M, Polu A, Geib S, et al.
J Med Chem
. 2025 Mar;
PMID: 40068019
Structure-activity relationship studies were performed on a library of synthesized compounds based on previously identified tau ligands. The top 13 new compounds had values in the range of 5-14 nM...
2.
Lindberg A, Murrell E, Tong J, Mason N, Sohn D, Sandell J, et al.
Nat Commun
. 2024 Jun;
15(1):5109.
PMID: 38877019
Positron emission tomography (PET) imaging of tau aggregation in Alzheimer's disease (AD) is helping to map and quantify the in vivo progression of AD pathology. To date, no high-affinity tau-PET...
3.
Graham T, Lindberg A, Tong J, Stehouwer J, Vasdev N, Mach R, et al.
J Med Chem
. 2023 Jul;
66(15):10628-10638.
PMID: 37487189
A chemical fingerprint search identified Z3777013540 (1-(5-(6-fluoro-1-indol-2-yl)pyrimidin-2-yl)piperidin-4-ol; ) as a potential 4R-tau binding ligand. Binding assays in post-mortem Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) brain...
4.
Lindberg A, Knight A, Sohn D, Rakos L, Tong J, Radelet A, et al.
ACS Chem Neurosci
. 2021 Jan;
12(4):596-602.
PMID: 33497190
CBD-2115 was selected from a library of 148 compounds based on a pyridinyl-indole scaffold as a first-in-class 4R-tau radiotracer. In vitro binding assays showed [H]CBD-2115 had a value of 6.9...
5.
Stehouwer J, Birnbaum M, Voll R, Owens M, Plott S, Bourke C, et al.
Bioorg Med Chem
. 2020 Aug;
28(19):115660.
PMID: 32747078
No abstract available.
6.
Abrahamson E, Stehouwer J, Vazquez A, Huang G, Mason N, Lopresti B, et al.
Nucl Med Biol
. 2020 May;
92:85-96.
PMID: 32471773
Introduction: Positron emission tomography (PET) using radiolabeled amyloid-binding compounds has advanced the field of Alzheimer's disease (AD) by enabling detection and longitudinal tracking of fibrillar amyloid-β (Aβ) deposits in living...
7.
Stehouwer J, Bourke C, Owens M, Voll R, Kilts C, Goodman M
Bioorg Med Chem Lett
. 2015 Oct;
25(22):5111-4.
PMID: 26456805
Compounds 1-14 were synthesized in a search for high-affinity CRF1 receptor ligands that could be radiolabeled with (11)C or (18)F for use as positron emission tomography (PET) radiotracers. Derivatives of...
8.
Stehouwer J, Goodman M
Tetrahedron Lett
. 2015 Aug;
56(30):4480-4482.
PMID: 26309335
The -fluoro-2-butenyl group has been previously utilized as an -substituent on several nortropanes for imaging the dopamine transporter with positron emission tomography. We report here a simplified and shorter synthesis...
9.
Stehouwer J, Birnbaum M, Voll R, Owens M, Plott S, Bourke C, et al.
Bioorg Med Chem
. 2015 Jul;
23(15):4286-4302.
PMID: 26145817
A series of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines were synthesized and evaluated as potential positron emission tomography (PET) tracers for the corticotropin-releasing factor type-1 (CRF1) receptor. Compounds 27, 28, 29, and 30 all displayed...
10.
Stehouwer J, Goodman M
J Labelled Comp Radiopharm
. 2013 Nov;
56(3-4):114-9.
PMID: 24285317
The serotonin transporter (SERT) has been implicated in a variety of neuropsychiatric disorders including depression, anxiety, and suicide, and is the target of the selective serotonin reuptake inhibitor (SSRI) class...